Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133

Citi analyst Mohit Bansal reiterated a Buy rating and $150.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN).

• Analyst is buyer on weakness.
• Sees FV around $131 to $133 per share.
• Says while weakness is justified, there is still value in the equity.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $112.17 yesterday.

You May Also Be Interested In

• BMO Capital Reiterates Market Perform Rating on On Holding AG (ONON)
• Envista Holdings Corp. (NVST) PT Lowered to $27 at UBS, Neutral Rating Maintained
• Desjardins Reiterates Buy Rating on Cambria Gold Mines Inc (CAMB:CN)